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The musculoskeletal system generates, absorbs and transmits force, enabling functional 
movement. Given this mechanical role, it follows that musculoskeletal tissues adapt to 
mechanical demands. Mechanical forces direct musculoskeletal cellular activities, altering 
tissue mass, structure and/or quality (figure 1).1 The net result is altered tissue-level stresses 
and strains to applied loads and, subsequently, altered injury risk.
Therapists have long identified the therapeutic potential of mechanical forces. Nearly every 
rehabilitation intervention introduces mechanical forces, irrespective of whether they are 
generated extrinsically (eg, via external modalities) or intrinsically (eg, via physical 
activity). These ‘mechanotherapies’ harness musculoskeletal mechanosensitivity to induce 
adaptation; however, how the adaptation occurs remains underappreciated.
Khan and Scott2 previously introduced readers of BJSM to the concept of 
mechanotransduction, whereby biophysical forces are converted into cellular and molecular 
responses. For musculoskeletal tissues to adapt to loading, the mechanical signal must be 
transmitted to the cell microenvironment and for the cell to possess sensory machinery 
(mechanocoupling) (figure 2A). The signal must subsequently be converted into a 
biochemical response (biochemical coupling), which is propagated to other nearby effector 
cells via the release of stored molecules or transmitted to the nucleus to induce expression of 
mechanosensitive genes (figure 2B). The effector cells ultimately bring about adaptation by 
altering extracellular matrix (ECM) synthesis and/or degradation (effector response).
Understanding mechanobiology and decoding mechanotransduction pathways extends 
beyond scientific curiosity. Altered mechanotransduction contributes to musculoskeletal 
disorders, ranging from osteoporosis and osteoarthritis to muscular dystrophies and 
sarcopenia.3 Altered mechanoadaptation in sports medicine contributes to injury risk, with 
athletes exhibiting less adaptation being at greater risk. The ability to identify athletes 
exhibiting factors that alter musculoskeletal mechanosensitivity is important. While not yet a 
clinical reality, the application of omic-based technologies (eg, genomics, proteomics, 
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metabolomics) may permit personalised medicine approaches to identifying and 
manipulating mechanosensitivity issues in individual athletes so as to optimise adaptation.
While we await the evolution of personalised medicine approaches, there are ways wherein 
knowledge of mechanotransduction can be presently applied. By understanding the forces to 
which musculoskeletal cells respond, it is possible to develop novel means of introducing 
those forces. This has been the premise of pre-existing mechanotherapies, such as 
therapeutic ultrasound and low-intensity vibration therapy. Although the efficacy of the latter 
modalities remains questioned, they provide examples of how microscopic forces induce 
cellular and tissue adaptation. As the stimuli to which cells respond are further defined, new 
mechanotherapies will be developed. These may particularly benefit emerging regenerative 
medicine techniques wherein cellular stimulation may be desired in the absence of tissue 
deformation (eg, in scenarios of restricted load bearing).
Appreciation of the machinery via which cells sense mechanical signals (mechano-coupling) 
informs load dosing parameters, among other things. The mechanosensor mechanism/s 
within musculoskeletal cells desensitise or become ‘deaf’ to persistent stimulation. Part of 
this is attributed to transmembrane receptors called integrins, some of which connect 
extracellularly to ECM proteins and intracellularly to the cytoskeleton. In response to 
mechanical loading, the ECM-integrin cytoskeletal axis induces cytoskeletal remodelling to 
stiffen musculoskeletal cells and temporarily reduce mechanosensitivity. Understanding 
factors contributing to cellular desensitisation and subsequent resensitisation, it is possible to 
design better loading regimes. This has best been illustrated in the skeleton where repetitive 
loading yielded diminishing bone mass gains, but inclusion of rest periods on orders of 
magnitude from seconds, hours and weeks between loading cycles and bouts enhanced 
gains.4 Preliminary evidence suggests the desensitisation phenomenon also occurs in 
tendon.5
Biochemical coupling of mechanical stimuli into molecular responses represents the most 
exciting target for manipulating mechanotransduction. Identifying molecules involved in 
mechanotransduction may reveal novel targets for therapeutic intervention that 
independently induce adaptation or have additive effects when combined with 
mechanotherapies. More interestingly, molecular targeting may sensitise 
mechanotransductive pathways such that superimposed loading results in synergistic 
adaptation. As an example, parathyroid hormone (PTH) therapy and mechanical stimuli both 
act through the PTH type 1 receptor. By introducing load to coincide with peak PTH 
receptor sensitisation, greater than summative skeletal adaptation is induced.6
Therapists should also consider potential negative interactions between mechanotherapies 
and biologically active compounds. An example of one such interaction is the combined 
effects of non-steroidal anti-inflammatory drugs (NSAIDs) and loading. Loading results in 
rapid cyclooxygenase-2 expression and release of prostaglandins, culminating in collagen 
(ie, ECM) synthesis. NSAIDs administered before mechanical loading inhibit 
cyclooxygenase expression and prostaglandin release to blunt bone, muscle and tendon 
adaptive responses.78
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As biological advancements continue, there is a need for therapists to understand the 
principals of mechanobiology and how mechanotherapies augment tissue responses at the 
cellular and molecular levels. By understanding the mechanical stimuli to which 
musculoskeletal cells best respond, and the mechanisms these cells use to convert 
mechanical signals into molecular responses, therapists may be able to use the force to 
augment the response of musculo-skeletal cells to mechanical stimuli. The net result will be 
additive or synergistic facilitation of tissue adaptation and a subsequent reduction in injury.
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Figure 1. 
Mechanical forces direct cellular activities to induce tissue adaptation. Extrinsically and 
intrinsically generated mechanical forces load musculoskeletal tissues, with the 
characteristics of the resultant tissue forces being dependent on the ability of the tissue to 
resist those forces. Tissue forces are transmitted to the micromechanical environment of 
resident cells, with cellular mechanical properties influencing the characteristics of the 
cellular forces. Cells can modify their micromechanical environment via cytoskeletal 
rearrangement, which feedbacks to alter cellular sensitivity to incoming forces. When 
cellular forces are sufficient, the cell initiates a molecular response, which ultimately alters 
synthesis and/or degradation of the extracellular matrix. The latter alters tissue mechanical 
properties, which feeds back to influence tissue forces. (Reprinted from Thompson et al,1 by 
permission of Oxford University Press and the American Physical Therapy Association.)
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Figure 2. 
A variety of extracellular receptors activate an overlapping network of mechanosensitive 
pathways. (A) Musculoskeletal cells can sense incoming mechanical signals using a diverse 
group of transmembrane mechanosensitive proteins (‘mechanosensors’), including stretch-
activated ion channels, cell-membrane spanning G protein-coupled receptors, growth-factor 
receptors and integrins. The mechanical stimulation of these proteins can lead to changes in 
their affinity to binding partners or ion conductivity. (B) Mechanical stimulation of the 
mechanosensors and alteration in their binding capacity or ion conductivity converts the 
mechanical signal into a biochemical signal (‘biochemical coupling’) triggering intracellular 
signalling cascades. Many of the pathways overlap sharing signalling molecules. The 
convergence of the pathways results in the activation of select transcription factors, 
including nuclear factor of activated T cells, nuclear factor-κβ, activator protein 1, GATA4 
(a member of the transcription factor family characterised by the ability to bind the DNA 
sequence ‘GATA’) and signal transducer and activator of transcription factors. The 
transcription factors translocate to the nucleus and modulate the expression of a panel of 
mechanosensitive genes, including early growth response 1, lex1, Fos, Jun and 
cyclooxygenase-2. Ultimately, the net sum of gene-expression reprogramming determines 
the functional response of the cell to a mechanical stimulus. Akt/PKB, protein kinase B; 
AP1, activator protein 1; CaMK, calcium/calmodulin-dependent kinase; Cox2, 
cyclooxygenase-2; DAG, diacyl-glycerol; Egr1, early growth response 1; ERK, extracellular 
signal-regulated kinase; FAK, focal adhesion kinase; IP3, inositol triphosphate; JNKs, c-Jun 
N-terminal kinases; MEK, mitogen-activated protein kinase; MEKK, mitogen-activated 
protein kinase kinase; MLCK, myosin light-chain kinase; NFAT, nuclear factor of activated 
T cells; NF-κβ, nuclear factor-κβ; NO, nitric oxide; NOS, nitric oxide synthase; PAK, p21-
activated kinase; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PLC, 
phospholipase C; Raf, rapidly accelerated fibrosarcoma kinase; Ras, rat sarcoma small 
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GTPase; STATs, signal transducer and activator of transcription factors. (Reprinted from 
Thompson et al,1 by permission of Oxford University Press and the American Physical 
Therapy Association.)
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